Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system

Tsung Ying Lee, Hsuan Ying Chen, Tsai Yun Chen, Sin Syue Li, Wei Tse Fang, Yao Chun Wen, Yu Wen Lo, Huang Tz Ou

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system'. Together they form a unique fingerprint.

Business & Economics

Medicine & Life Sciences

Social Sciences